Efficacy of Ranolazine in treating ventricular premature beats

Not Applicable

• Conditions: premature ventricular beats, ventricular premature depolarization, premature ventricular complexes, premature ventricular contraction.; Ventricular premature depolarization; I49.3

• Registration Number: IRCT20220515054863N2
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

Minimum age of 18
PVC burden between 10 to 30 percent among whole beats

Exclusion Criteria

Patients with Atrial Fibrillation (AF)
Patients diagnosed with ischemic ventricular tachycardia (VT)
Patients with a history of serious ventricular tachyarrhythmias in the past 4 weeks (e.g., sustained ventricular tachycardia and ventricular fibrillation)
Patients who have a QT interval higher than 550 milliseconds or consume medications that prolong the QT interval
Patients with a heart transplant
Patients undergoing dialysis
Patients with a creatinine clearance below 30 ml/min or a blood creatinine over 2.5 mg/dl
Patients with moderate to severe hepatic dysfunction
Patients receiving metformin with a dose extending 1000 mg Bid
Patients receiving simvastatin with a daily dose extending 20 mg
Patients receiving Dabigatran
Patients receiving a CYP3A4 inhibitor (Ketoconazole, Clarithromycin, Ritonavir, Diltiazem, Fluconazole, Erythromycin, Verapamil or grapefruit juice)
Patients with a history of Ranolazine consumption in the past two months
Patients who have previously discontinued Ranolazine due to side effects
Pregnant or breastfeeding patients, or patients planning for pregnancy during the study period
Patients without informed consent

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Difference in PVC burden on holter before and after treatment. Timepoint: 30 days. Method of measurement: Holter monitoring at the time of enrollment and 30 days after receiving therapy.

Secondary Outcome Measures

Name	Time	Method
Any patient-reported side effects. Timepoint: 30 days. Method of measurement: interview.